Introduction
Penile cancer remains the rarest genital malignancy in men. However, up to 20% of cases are lethal (1) , with the presence of node metastasis representing the greatest independent survival predictor (2, 3) . Not surprisingly, early inguinal lymphadenectomy (iLAD) reduces the mortality rate up to 50% compared technique relies on the principle that metastatic spread occurs after tumor cells root in the first drainage station: positivity of this site should prompt for further surgical management; viceversa, surveillance may be undertaken (7, 8) . Several groups published their experience of penile cancer DSNB yielding promising results and improved outcomes over the years (9) . Currently, the largest prospective series reported a >90% sensitivity together with a low morbidity rate (6) .
Our aim is to report the results of a contemporary series of DSNB with an intermediate to long-term follow-up focusing on its ability to drive patient management.
Methods

Study features and criteria
We performed a retrospective analysis of prospectively collected data of consecutive men with histologically proven ≥T1 or ≥G2 cN0 penile cancer who underwent dynamic sentinel node lymphoscintigraphy and subsequent biopsy (DSNB) during primary tumor excision at San Giovanni Battista Hospital, Turin, Italy, from June 2009 to June 2015. Antibiotic prophylaxis was performed with a single-dose cefuroxime 2 g intravenous injection at induction.
Patients with <18 months follow-up or with local recurrence after primary curative treatment were excluded. All included men had negative clinical examination and negative imaging for lymph node involvement (abdominal and pelvic computed tomography scan). A false-negative DSNB was defined as regional nodal recurrence after a negative DSNB within 18 months in the absence of a new primary tumor or recurrence (10) . All patients with positive DSNB underwent bilateral iLAD and eventual pelvic lymphadenectomy, if deemed appropriate. Follow-up was performed with physical examination every 3 months for the first 2 years and ultrasound every 3 months for the first year and every 6 months during the second year.
American Society of Anesthesiologists status and Charlson comorbidity index were recorded for each patient and complications were graded according to the Clavien-Dindo classification, following European Association of Urology Guideline recommendations, and were separated from the ones related to the main surgical procedures (11) . Data were collected and verified by a dedicated physician (M.P.).
Dynamic sentinel lymph node biopsy
The day before surgery, all patients received intradermal injection of technetium-99m nanocolloid (Nanocoll, GE Healthcare) in the peritumoral area. Dynamic imaging was performed 30 and 120 minutes postinjection and static imaging at 120 minutes through a dual-head gamma camera (ADAC Vertex, Milpitas) with the sentinel node site being marked on the groin skin.
Thirty minutes before surgery, 1 mL of patent blue dye (Laboratoire Guerbet) was intradermally injected in the tissues surrounding the disease site. Intraoperative identification of the nodes was performed by a multidisciplinary team including a senior urologic surgeon (O.S.) and a senior consultant dermatologist (V.C.) using preoperative imaging, a gamma de- No intraoperative examination of the removed lymph nodes was performed because the frozen sections may be inadequate to assess the presence of micrometastases (11) . All retrieved nodes were processed and analyzed by a dedicated senior pathologist (>20 years experience in penile cancer).
Statistical analysis
Statistical analyses were performed using STATA13.0-Statistics/DataAnalysis. To calculate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), a true negative patient was defined as a patient who underwent negative DSNB and negative iLAD and/or an 18-month followup negative for penile cancer nodal metastasis.
Results
Patients and dynamic sentinel node biopsy
Thirty-five men with penile cancer diagnosis underwent DSNB. Baseline patient features are summarized in Table I .
Different surgical procedures at the time of DSNB are listed in Table II . The vast majority of penile cancers were organconfined to the internal penis chambers (≤T2 = 85.71%), with well to moderately differentiated histology (≤G2a = 85.71). Only 5 patients needed partial or total amputation (Tab. II). Among patients with positive findings, 1 died of cardiologic disease but was free from penile cancer, whereas 2 died of penile cancer despite lymphadenectomy performed after positive sentinel lymph node biopsy.
Of the DSNB-negative patients, 2 developed nodal penile cancer recurrence. One man with T2G2 disease had negative scintigraphy and did not undergo perioperative node biopsy revealing bilateral penile cancer nodal involvement at subsequent iLAD. The patient died of penile cancer after 4 months. Another man with T1bG2 underwent monolateral left node biopsy due to negative contralateral scintigraphy. At 17 months, he underwent extended lymphadenectomy due to suspicious imaging, which revealed histologically positive right inguinal and pelvic node. Despite adjuvant chemotherapy, the patient died of penile cancer at 24 months from lymphadenectomy.
After a median follow-up of 42 months (interquartile range range 30-78 months), overall, DSNB sensitivity and specificity were 93.3% and 25.45%, respectively, whereas PPV and NPV were 25.45% and 93.3% (Tab. IV).
If considering only men with scintigraphy-detected inguinal nodes, sensitivity and specificity changed to 50% and 80%, whereas PPV and NPV were 25% and 92.3%, respectively (Tab. V).
Discussion
One of the crucial steps of penile cancer management remains whether to perform iLAD in cN0 patients as the procedure proved to be life-saving, especially in case of micrometastatic disease. On the one hand, despite promising imaging, its current performance in the detection of Overall, 70 cN0 groins were analyzed. Lymphoscintigraphy had a per groin 80% detection rate, being positive bilaterally in 21 cases (60%), and on the left or right groin only in 9 (12.86%) and 5 (7.14%) of the cases, respectively. Nonvisualized groins were not surgically explored. Overall, 33 right (≥2 positive nodes in n = 7) and 40 left (≥2 in n = 9) lymph nodes were identified, all being cN0 at clinical and radiologic examination.
The average postoperative hospitalization was 5 days (range 2-10 days). No biopsy-related major complications occurred. In 2 cases (5.7%), a Clavien-Dindo Event Class II was recorded (1 case of bleeding and 1 case of groin wound infection). In no cases did DSNB prolong the postoperative course related to penile cancer surgery.
In total, 109 nodes were removed from 56 groins (26 right groins, n = 54 nodes; 30 left groins, n = 55 nodes; Tab. III).
Positive and negative node biopsy in relation to scintigraphy are shown in Table IV . Overall, 15 nodes were positive in 9 patients. In 1 case, 2 positive lymph nodes were identified for neoplastic cells on the same side. A bilateral contemporary penile cancer involvement of sentinel lymph nodes was found in 4 cases.
Follow-up
Of the 9 patients with positive nodes at DSNB, 1 was lost at the follow-up, whereas the other 8 subsequently penile cancer nodal involvement is poor (12) . On the other hand, tools such as physical examination and histology, with nodes being positive in up to almost intermediate-to highrisk disease cN0 men, only allow a rough estimation of nodal involvement probability (12) .
In the last decade, the prophylactic role of iLAD for high-risk disease started being questioned (13) . The same holds even more true for intermediate-risk disease. The important iLAD comorbidities must be weighed against oncologic risks related to surveillance, claiming for a patient-tailored approach. Indeed DSNB represents not only a major advance in penile cancer decision-making but a breakthrough that changed penile cancer's natural course as its use prolongs cancer-specific survival (14) . In the current study, we evaluated the role of perioperative DSNB in cN0 penile cancer patients with an intermediate to long-term follow-up at an Italian tertiary referral center.
Among the detected groins, none of the histologically negative at DSNB cases subsequently developed disease within a minimum of 18 months follow-up. To our knowledge, we describe the first series with a 100% per groin NPV: this is indeed encouraging as false-negative DSNB may negatively impact on patient survival (9, 15) . In case of a positive scintigraphy and negative sentinel node, the patient should be reassured and maintained on standard surveillance protocols. While some centers achieved an almost 50% reduction of false-negative cases after complementation of the DSNB protocol with fine needle aspiration and ultrasound or surgery (13), this is not currently applicable to our series as the standard pathway always ruled out cancer correctly when the primary drainage site was detected. Dynamic sentinel node biopsy is a complex multistep procedure and, as suggested by others (13, 16) , the dedicated multidisciplinary policy adopted at our institution contributed to optimize DSNB results.
An important concern remains what to do in men with negative scintigraphy and how to optimize DSNB detection rate. Although in 80% of the groins the primary drainage site was identified and biopsied, in our experience 2 cases in nonassessed men recurred, both subsequently dying because of penile cancer. So what should be done with non uptaking groins? Factors favoring nonvisualization include (13, 17) primary tumor-related edema and/or direct lymphatic blockage, previous inguinal surgery possibly disrupting lymphatics anatomy, low tracer uptake, and suboptimal 99mTc dosage. Apart from the DSNB protocol, none of them can be modified to enhance perioperative detection rate and until new tracers will become available, 99mTc using blue dye at the standard dosage remains the best proved way to perform DSNB (9) . In a recent work reviewing the records of 166 DSNB cases, Sahdev and colleagues (17) identified 7 noncaptant groins: all had repeated scintigraphy within 45 days, with 6 having a successful DSNB. Although not assessed in our work, there is a need for appropriate counseling for men with noncaptant nodes. This should include as primary alternatives a repeat DSNB or a superficial iLAD, with surveillance being proposed to men with <T2, no poorly differentiated histology, and no vascular and/or perineural invasion as delay in treatment of nodal metastasis must be avoided.
In line with other studies, complications were low. Fewer than 5% of the cohort had DSNB-related drawbacks and no major events were recorded (15) . More importantly, in none of the cases did DSNB prolong hospital stay compared to the primary site penile cancer surgery. Although postoperative DSNB also proved excellent for diagnostic accuracy (18) , this supports perioperative use of DSNB.
Finally, we experienced a low PPV, with only 1 in 4 men undergoing iLAD being positive at final histology. The high discrepancy between DSNB and iLAD-positive patients is likely explained by the clustering of nodes (8) with approximately 2 nodes being removed per groin. Due to node proximity, it is not always possible to identify a single sentinel node as corresponding to the captating one and in some cases metastatic and micrometastatic sites may all have been removed through DSNB. While this may allow us to define DSNB as curative in some cases, it is crucial to stress that a histologically positive node at DSNB remains an absolute indication to perform bilateral iLAD.
This study does not come without its limitations as current excellent NPV and relatively high detection rate need to be confirmed on a higher number of patients using a prospective evaluation. Similarly, although absence of a learning curve for DSNB has been demonstrated (15), the results reflect our initial experience rather than an established standard. However, our series is consonant with contemporary criteria using a standardized protocol and a dedicated multidisciplinary team, and thus well represents the recommended standard for penile cancer management.
Future studies will need to assess DSNB on a higher number of patients, investigating how to optimize detection and reduce the false-negative rate. Hopefully the advent of new tracers (12) together with increasing imaging performance and centralization of penile cancer management will favor such improvement. Currently, perioperative DSNB after blue dye injection should be considered as the standard for ≥T1 penile cancer as it optimizes patient management and care.
Conclusion
Perioperative DSNB performed at a tertiary referral center using a multidisciplinary dedicated team is a safe procedure with promising results including a good overall detection rate and absence/minimization of false-negatives if the captating At least 18 months of follow-up. iLAD/follow-up positive = patients who underwent iLAD positive for penile cancer; iLAD/follow-up negative = patients who underwent iLAD due to positive node biopsy and had no evidence of penile cancer or patients with a follow-up negative for penile cancer nodal metastasis. One patient was lost to follow-up after a positive dynamic sentinel node biopsy.
node is biopsied. Despite a low PPV, iLAD remains an absolute indication in case of positive DSNB. Future studies will need to investigate how to optimize detection rate and manage patients for whom a sentinel node was not identified.
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